In a large cohort study of RA patients treated with adalimumab, a fully human mAb also targeting TNFα, Bartelds et al. [16] reported that 76 (28%) of 272 patients developed antidrug antibodies (ADAs) after three years of treatment. This evidence concerns the gene TNF and rheumatoid arthritis.